ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination

Inclusion criteria: * Type 2 diabetes mellitus patients * Patients with HbA1c \>or= 7.0% and \< 10.0% * Patients not currently treated with any oral antidiabetic drugs (OADs) Exclusion criteria: * Participation in other investigational Clinical Trial * Current temporary insulin treatment: gestational diabetes, pancreas cancer, surgery etc. * Women who are pregnant and lactating * Type 1 diabetes mellitus patients * Treatment with antihypertensive Angiotensin-Converting Enzyme (ACE)-Inhibitors and/or Angiotensin II Receptor Blocker (ARB) or has just stopped treatment for less than two months * Treatment with lipid lowering agent statins or has just stopped treatment for less than two months * Known hypersensitive to any of the excipients of Amaryl-M, sulphonylureas, sulfonamides or biguanide * Patients with active smoking or history of smoking cessation less than 2 months * Patients with history of severe hepatic dysfunction * Patients with serum creatinine \>or= 1.5 mg/dL (male) and \>or= 1.4 mg/dL (female) * Patients with congestive heart failure requiring pharmacologic treatment * Treatment with antifungal agent especially Miconazole The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.